Latest Articles
- Using C-reactive protein to assess cardiovascular disease risk
CRP is now a recognized cardiac test. But who should he tested?
Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosisWe have an important new drug for osteoporosis. Now who should get it? And who will pay for it?
- The promise of molecular biology: Efficacy, safety, wallet depletion
Molecular biology is entering its second wave, with effective but expensive treatments. Recombinant human parathyroid hormone (PTH) is a case in point.
- Amiodarone-induced thyrotoxicosis: Diagnostic and therapeutic strategies
It is difficult but important to distinguish the two types of amiodarone-induced thyrotoxicosis.
- Managing weight gain as a side effect of antidepressant therapy
Some drugs are more apt to cause weight gain than others; one should inform and work with the patient.
- In refractory temporal lobe epilepsy, consider surgery sooner
Epilepsy surgery is perhaps the most underused therapy in all of medicine today.
- New advances transform the management of women with abnormal Pap tests
We review the new thin-layer slide system, the new HPV test, the 2001 reporting system for Pap tests, and new management guidelines.